AU2019278927A1 - Devices and systems for gastrointestinal microbiome detection and manipulation - Google Patents

Devices and systems for gastrointestinal microbiome detection and manipulation Download PDF

Info

Publication number
AU2019278927A1
AU2019278927A1 AU2019278927A AU2019278927A AU2019278927A1 AU 2019278927 A1 AU2019278927 A1 AU 2019278927A1 AU 2019278927 A AU2019278927 A AU 2019278927A AU 2019278927 A AU2019278927 A AU 2019278927A AU 2019278927 A1 AU2019278927 A1 AU 2019278927A1
Authority
AU
Australia
Prior art keywords
subject
sibo
microorganism
antimicrobial agent
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019278927A
Other languages
English (en)
Inventor
Mitchell Lawrence Jones
Shaoying LEE
Sharat Singh
Christopher Loren WAHL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bt Bidco Inc
Original Assignee
Bt Bidco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bt Bidco Inc filed Critical Bt Bidco Inc
Publication of AU2019278927A1 publication Critical patent/AU2019278927A1/en
Assigned to BIORA THERAPEUTICS, INC. reassignment BIORA THERAPEUTICS, INC. Amend patent request/document other than specification (104) Assignors: PROGENITY, INC.
Assigned to BT BIDCO, INC. reassignment BT BIDCO, INC. Request for Assignment Assignors: BIORA THERAPEUTICS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/02—Instruments for taking cell samples or for biopsy
    • A61B10/04—Endoscopic instruments, e.g. catheter-type instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B2010/0061—Alimentary tract secretions, e.g. biliary, gastric, intestinal, pancreatic secretions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
AU2019278927A 2018-06-01 2019-05-31 Devices and systems for gastrointestinal microbiome detection and manipulation Abandoned AU2019278927A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862679659P 2018-06-01 2018-06-01
US62/679,659 2018-06-01
US201862751209P 2018-10-26 2018-10-26
US62/751,209 2018-10-26
US201962829225P 2019-04-04 2019-04-04
US62/829,225 2019-04-04
PCT/US2019/034795 WO2019232295A1 (en) 2018-06-01 2019-05-31 Devices and systems for gastrointestinal microbiome detection and manipulation

Publications (1)

Publication Number Publication Date
AU2019278927A1 true AU2019278927A1 (en) 2020-12-24

Family

ID=66913047

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019278927A Abandoned AU2019278927A1 (en) 2018-06-01 2019-05-31 Devices and systems for gastrointestinal microbiome detection and manipulation

Country Status (7)

Country Link
US (1) US20210386367A1 (https=)
EP (1) EP3802850B1 (https=)
JP (1) JP7421504B2 (https=)
CN (1) CN112400024B (https=)
AU (1) AU2019278927A1 (https=)
CA (1) CA3102255A1 (https=)
WO (1) WO2019232295A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4563094A1 (en) * 2023-11-28 2025-06-04 Stichting IMEC Nederland Ingestible device and method for sampling material using a heat dependent actuating mechanism

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201720162D0 (en) * 2017-12-04 2018-01-17 Univ Oxford Innovation Ltd Method
US20200330004A1 (en) * 2019-04-17 2020-10-22 Khan Arif Wahid Methods and devices for in situ detection of a composition of a fluid within a gastrointestinal tract
CA3137620A1 (en) * 2019-04-30 2020-11-05 Infectotest Gmbh Electrochemical d-lactate measurement for diagnosis and prognosis of an infectious disease
US11763920B2 (en) 2019-07-31 2023-09-19 Dig Labs Corporation Mucus analysis for animal health assessments
EP4004938A1 (en) 2019-07-31 2022-06-01 Dig Labs Corporation Animal health assessment
US12514569B2 (en) * 2019-12-16 2026-01-06 Eli Lilly And Company Capsule for gastrointestinal sampling
EP4149607A4 (en) * 2020-05-13 2024-07-31 The Trustees of Indiana University USE OF AN ELECTRIC CURRENT OR FIELD TO MANAGE THE RISK OF INFECTION BY ANTIMICROBIAL-RESISTANT MICROORGANISMS
CN112190291B (zh) * 2020-10-13 2023-06-06 山西农业大学 一种采集猪仔肠道微生态样本的定量采样装置
US20220208375A1 (en) * 2020-12-29 2022-06-30 Kpn Innovations, Llc. System and method for generating a digestive disease functional program
CN113640365B (zh) * 2021-08-12 2022-09-30 中国科学技术大学 生物样品中细菌鉴定及抗生素敏感性测试的分析方法
CN114235939B (zh) * 2021-12-15 2023-09-26 上海交通大学 一种肿瘤微环境细菌探针及其在基于成像质谱流式技术的肿瘤微环境细菌检测中的应用
CN114496278B (zh) * 2022-01-12 2022-09-27 广州保量医疗科技有限公司 肠道菌群移植配型的数据处理方法、系统、设备及介质
CN119317395A (zh) * 2022-05-20 2025-01-14 伊莱利利公司 可摄取胶囊装置
WO2023242741A1 (en) * 2022-06-13 2023-12-21 Novocure Gmbh Systems and methods for increasing intestinal absorption of therapeutic agents
US20260116956A1 (en) * 2022-06-21 2026-04-30 New York University Antibody based treatment to reduce gut bacterial glycan and associated bacteria
PL442950A1 (pl) * 2022-11-25 2024-05-27 Biomaxima Spółka Akcyjna Pasek testowy do wykrywania minimalnego stężenia hamującego (MIC)
PL442949A1 (pl) * 2022-11-25 2024-05-27 Biomaxima Spółka Akcyjna Pasek testowy do wykrywania minimalnego stężenia hamującego (MIC)
CN115820394B (zh) * 2022-12-09 2023-09-26 江苏徐淮地区淮阴农业科学研究所 猪肠道微生物标记检测装置
CN115778936B (zh) * 2022-12-16 2024-06-28 中国农业大学 松萝酸协同增效多黏菌素在抗革兰氏阴性细菌感染中的应用
CN116790402B (zh) * 2023-01-14 2024-05-14 西北农林科技大学 一株具有抗炎特性的单形拟杆菌菌株、培养方法及应用
WO2024225153A1 (ja) * 2023-04-27 2024-10-31 サントリーホールディングス株式会社 免疫活性化用組成物
CN116777309B (zh) * 2023-08-23 2023-10-27 四川省眉山益稷农业科技有限公司 一种有机肥发酵质量评价方法
WO2025075714A1 (en) * 2023-10-04 2025-04-10 Rowan University Point-of-care test diagnostic markers and adjuvant treatments for gastrointestinal diseases
CN117025808A (zh) * 2023-10-09 2023-11-10 美格医学检验所(广州)有限公司 一种病原微生物检测引物组合、试剂盒和检测方法
CN118121195B (zh) * 2024-05-06 2024-07-23 南昌大学第一附属医院 一种用于胃肠内生理环境的检测装置
CN120227512B (zh) * 2025-05-30 2025-08-08 华东理工大学 一种促口腔口咽瘘管修复的锰-聚多巴胺基有机-无机杂化凝胶材料及其制备方法
CN120574273B (zh) * 2025-08-05 2025-10-14 成都新朝阳作物科学股份有限公司 瘟克菌素、其应用及其制备方法、农药药剂和稻瘟病的防治方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4190328A (en) 1978-12-01 1980-02-26 Levine Robert A Process for detection of blood-borne parasites
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
WO1989012232A1 (en) 1988-06-08 1989-12-14 London Diagnostics, Inc. Assays utilizing sensitizer-induced production of detectable signals
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
ES2062519T5 (es) 1989-03-21 2003-07-16 Immune Response Corp Inc Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t.
IL95125A (en) 1989-07-19 1995-07-31 Vandenbark Arthur Allen T cell peptides receive a method for their selection and preparation, and pharmaceutical preparations containing them
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5314805A (en) 1991-10-28 1994-05-24 Molecular Probes, Inc. Dual-fluorescence cell viability assay using ethidium homodimer and calcein AM
WO1995006877A1 (en) 1993-09-03 1995-03-09 Behringwerke Ag Fluorescent oxygen channeling immunoassays
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US6224379B1 (en) 1998-10-02 2001-05-01 Trustees Of Tufts College Method for shaping an adhesive material
US6331530B1 (en) 1999-07-13 2001-12-18 The Trustees Of Columbia University In The City Of New York Hydrophilic carrier for photosensitizers that cleaves when they catalyze the formation of singlet oxygen
PL218223B1 (pl) * 2000-06-21 2014-10-31 Cubist Pharmaceuticals Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny
US7635571B2 (en) 2000-12-07 2009-12-22 Siemens Healthcare Diagnostics Products Gmbh Amplified signal in binding assays
AU2003267936A1 (en) * 2002-01-10 2003-12-31 Idexx Laboratories, Inc. Methods and devices for the detection of pathogenic microorganisms and their antimicrobial susceptilbility
JP2006509183A (ja) 2002-03-05 2006-03-16 アクララ バイオサイエンシーズ， インコーポレイテッド 膜結合増感剤を用いる多重分析
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
AU2004235298A1 (en) 2003-04-25 2004-11-11 Janssen Pharmaceutica N.V. Preservation of RNA in a biological sample
US20030190313A1 (en) 2003-06-05 2003-10-09 Rossignol Daniel P. Diagnostic tests for anti-endotoxin core antibodies
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
KR20060092254A (ko) 2003-09-23 2006-08-22 라이트 사이언시즈 코포레이션 표적화된 ｐｄｔ 제제의 선택성을 증진시키는 표적 결합에의해 활성화된 일중항 산소 감광제
US7399608B2 (en) 2003-12-16 2008-07-15 Kimberly-Clark Worldwide, Inc. Microbial detection and quantification
US7833795B2 (en) 2004-08-24 2010-11-16 The Trustees Of The University Of Pennsylvania Assessment of cardiovascular risk using isoprostane biomarkers and COX-2 selective inhibitors
US20090176251A1 (en) 2008-01-08 2009-07-09 Binder Walter L Methods for Diagnosing Celiac Disease Based on the Level of Anti-Gliadin and Anti-tTG IgA and IgG Antibodies
US9848760B2 (en) * 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
GB2489193A (en) 2010-10-29 2012-09-26 Univ Warwick Ingestible sensor device to detect gases and VOCs in the gastrointestinal tract
US9149617B2 (en) 2010-12-23 2015-10-06 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8907081B2 (en) 2011-05-27 2014-12-09 Sharp Laboratories Of America, Inc. Long wavelength absorbing porphyrin photosensitizers for dye-sensitized solar cells
FR2986432B1 (fr) 2012-02-06 2014-03-14 Univ Lille Ii Droit & Sante Proteines 28kda gst provenant de schistosomes pour leur utilisation dans le traitement des maladies inflammatoires auto-immunes engendrant une reponse de type th1 et/ou th17
MX2015002210A (es) * 2012-08-29 2015-05-08 Salix Pharmaceuticals Inc Composiciones laxantes y metodos para tratar estreñimiento y enfermedades y condiciones gastrointestinales relacionadas.
EP2893032B1 (en) 2012-09-05 2018-01-17 Maximus Diagnostic Technologies LLC Methods and composition for detecting intestinal cell-barrier dysfunction
US8915863B2 (en) * 2012-11-16 2014-12-23 L. Zane Shuck In vivo device and method for researching GI tract processes, microbes, and variables associated with illnesses and diseases
JP2016521683A (ja) 2013-05-24 2016-07-25 ネステク ソシエテ アノニム 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
WO2014200816A1 (en) 2013-06-14 2014-12-18 Biotranex, Llc Method for measuring bile salt export transport and/or formation activity
WO2016036887A1 (en) 2014-09-02 2016-03-10 The Regents Of The University Of California Fluorescence assay for intestinal permeability
EP3194950A4 (en) 2014-09-02 2018-08-22 Royal Melbourne Institute Of Technology Gas sensor nanocomposite membranes
CN104473611B (zh) 2015-01-19 2018-01-30 吉林大学 具有超声波定位功能的胶囊内窥镜系统
WO2016197181A1 (en) 2015-06-12 2016-12-15 Royal Melbourne Institute Of Technology Nox gas sensor
WO2017068576A1 (en) * 2015-10-22 2017-04-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method and kit to test anti-microbial agents
JP2019508395A (ja) 2016-02-02 2019-03-28 マキシマス ダイアグノスティック テクノロジーズ エルエルシー 炎症性腸疾患の処置を改善するための腸管バリア機能の評価
WO2017173203A1 (en) 2016-03-31 2017-10-05 Mayo Foundation For Medical Education And Research Methods and materials for assessing intestinal permeability
AU2017295866A1 (en) * 2016-07-14 2019-01-17 Achaogen, Inc. Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
EP3500177A1 (en) * 2016-08-18 2019-06-26 Mitchell Lawrence Jones Systems for obtaining samples using ingestible devices
CA3036334A1 (en) * 2016-09-09 2018-03-15 Mitchell Lawrence Jones Systems and methods for extracting a sample from an ingestible device
WO2018106945A1 (en) * 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112441A1 (en) * 2016-12-15 2018-06-21 Progenity Inc. Ingestible device and associated methods

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4563094A1 (en) * 2023-11-28 2025-06-04 Stichting IMEC Nederland Ingestible device and method for sampling material using a heat dependent actuating mechanism

Also Published As

Publication number Publication date
JP7421504B2 (ja) 2024-01-24
EP3802850C0 (en) 2025-11-19
WO2019232295A1 (en) 2019-12-05
EP3802850B1 (en) 2025-11-19
JP2021525526A (ja) 2021-09-27
EP3802850A1 (en) 2021-04-14
US20210386367A1 (en) 2021-12-16
CN112400024A (zh) 2021-02-23
CN112400024B (zh) 2024-04-09
CA3102255A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
EP3802850B1 (en) Devices and systems for gastrointestinal microbiome detection and manipulation
US11547301B2 (en) Methods for collecting and testing bacteria containing samples from within the gastrointestinal tract
US20250082265A1 (en) Treatment of a disease of the gastrointestinal tract with an immunosuppressant
US20240252425A1 (en) Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
EP4233902A2 (en) Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US10980739B2 (en) Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US20210401895A1 (en) Treatment of a disease of the gastrointestinal tract with live biotherapeutics
EP3554344A1 (en) Treatment of a disease of the gastrointestinal tract with a tlr modulator
EP4108183A1 (en) Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: BIORA THERAPEUTICS, INC.

Free format text: FORMER NAME(S): PROGENITY, INC.

PC1 Assignment before grant (sect. 113)

Owner name: BT BIDCO, INC.

Free format text: FORMER APPLICANT(S): BIORA THERAPEUTICS, INC.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application